Open access
Open access
Powered by Google Translator Translator

RCT: Sintilimab plus a bevacizumab biosimilar versus sorafenib in unresectable hepatocellular carcinoma.

22 Jul, 2021 | 10:47h | UTC

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Sintilimab Plus Bevacizumab Biosimilar vs Sorafenib in Unresectable or Metastatic HBV-Associated Hepatocellular Carcinoma – The ASCO Post

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.